Treatment of asthma with drugs modifying the leukotriene pathway

New England Journal of Medicine

Volumn 340, Issue 3, 1999, Pages 197-206

  Drazen, Jeffrey M ^a   Israel, Elliot ^a   O'Byrne, Paul M ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CINALUKAST; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; MONTELUKAST; POBILUKAST; PRANLUKAST; THEOPHYLLINE; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BRONCHODILATATION; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; HUMAN; ICOSANOID METABOLISM; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

ANTI-ASTHMATIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ASTHMA; BRONCHODILATOR AGENTS; CHRONIC DISEASE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; RECEPTORS, LEUKOTRIENE;

EID: 0033590513     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199901213400306     Document Type: Review

References (110)

1. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76:4275-9.
2. Kellaway CH, Trethewie ER. Liberation of slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q J Exp Physiol 1940;30:121-45.
3. Drazen JM, Austen KF, Lewis RA, et al. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A 1980;77:4354-8.
4. Drazen JM, Lewis RA, Wasserman SI, Orange RP, Austen KF. Differential effects of a partially purified preparation of slow-reacting substance of anaphylaxis on guinea pig tracheal spirals and parenchymal strips. J Clin Invest 1979;63:1-5.
5. Dahlen SE, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980;288:484-6.
6. Weiss JW, Drazen JM, Coles N, et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982;216:196-8.
7. Griffin M, Weiss JW, Leitch AG, et al. Effects of leukotriene D on the airways in asthma. N Engl J Med 1983;308:436-9.
8. Smith LJ, Greenberger PA, Patterson R, Krell RD, Bernstein PR. The effect of inhaled leukotriene D4 in humans. Am Rev Respir Dis 1985;131: 368-72.
9. 4 and to methacholine in patients with asthma and normal controls. N Engl J Med 1986;315:480-4.
10. Hui KP, Lotvall J, Chung KF, Barnes PJ. Attenuation of inhaled allergen-induced airway microvascular leakage and airflow obstruction in guinea pigs by a 5-lipoxygenase inhibitor (A-63162). Am Rev Respir Dis 1991; 143:1015-9.
11. 4 and PAF receptor antagonists in decreasing antigen-induced airway microvascular leakage. Adv Prostaglandin Thromboxane Leukot Res 1995; 23:271-3.
12. Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E(4) and granulocytic infiltration into asthmatic airways. Lancet 1993;341:989-90.
13. Munoz NM, Leff AR. Blockade of eosinophil migration by 5-lipoxygenase and cyclooxygenase inhibition in explanted guinea pig trachealis. Am J Physiol 1995;268:L446-L454.
14. Coles SJ, Neill KH, Reid LM, et al. Effects of leukotrienes C4 and D4 on glycoprotein and lysozyme secretion by human bronchial mucosa. Prostaglandins 1983;25:155-70.
15. Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Respir Dis 1991;143:S96-S99.
16. Pasquale D, Chikkappa G. Lipoxygenase products regulate proliferation of granulocyte-macrophage progenitors. Exp Hematol 1993;21:1361-5.
17. 4 induced vascular smooth muscle cell proliferation: a possible role in myointimal hyperplasia. Thromb Haemost 1996;76:99-104.
18. 4 facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol 1995;269:L151-L157.
19. Markel P, Shu P, Ebeling C, et al. Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains. Nat Genet 1997;17: 280-4.
20. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
21. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-55.
22. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
23. Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. FASEB J 1991;5:2068-77
24. 2. Crit Rev Immunol 1997;17:225-83.
25. Dixon RA, Diehl RE, Opas E, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-4.
26. Coffey MJ, Wilcoxen SE, Peters-Golden M. Increases in 5-lipoxygenase activating protein expression account for enhanced capacity for 5-lipoxygenase metabolism that accompanies differentiation of peripheral blood monocytes into alveolar macrophages. Am J Respir Cell Mol Biol 1994;11:153-8.
27. Rubin P, Dube L, Braeckman R, et al. Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase. Agents Actions Suppl 1991;35:103-16.
28. 4. Proc Natl Acad Sci USA 1994;91:7663-7.
29. 4 hydrolase: a zinc metalloenzyme with dual enzymatic activities. Biochim Biophys Acta 1991;1080:96-102.
30. Lim BK, Owen WF Jr, Austen KF, Soberman RJ. The identification of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J Biol Chem 1989;264:12885-9.
31. 4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J Biol Chem 1996;271:9675-82.
32. Sala A, Voelkel N, Maclouf J, Murphy RC. Leukotriene E4 elimination and metabolism in normal human subjects. J Biol Chem 1990;265:21771-8.
33. Maclouf J, Antoine C, De Caterina R, et al. Entry rate and metabolism of leukotriene C4 into vascular compartment in healthy subjects. Am J Physiol 1992;263:H244-H249.
34. Murphy RC, Wheelan P. Pathways of leukotriene metabolism in isolated cell models and human subjects. In: Drazen JM, Dahlen SE, Lee T, eds. 5-Lipoxygenase products in asthma. New York: Academic Press, 1998:87-123.
35. Wetterholm A, Haeggstrom JZ. Leukotriene A4 hydrolase: an anion activated peptidase. Biochim Biophys Acta 1992;1123:275-81.
36. Minami M, Ohno S, Kawasaki H, et al. Molecular cloning of a cDNA coding for human leukotriene A4 hydrolase: complete primary structure of an enzyme involved in eicosanoid synthesis. J Biol Chem 1987;262:13873-6.
37. Kawashima H, Kusunose E, Thompson CM, Strobel HW. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys 1997;347:148-54.
38. Yokomizo T, Ogawa Y, Uozumi N, Kume K, Izumi T, Shimizu T. cDNA cloning, expression, and mucagenesis study of leukotriene B4 12-hydroxydehydrogenase. J Biol Chem 1996;271:2844-50.
39. Coleman RA, Eglen RM, Jones RL, et al. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostaglandin Thromboxane Leukot Res 1995;23:283-5.
40. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis, Nature 1997;387:620-4.
41. Piper PJ. Pharmacology of leukotrienes. Br Med Bull 1983;39:255-9.
42. Serhan CN, Haeggstrom JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J 1996;10:1147-58.
43. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci U S A 1980;77: 3710-4.
44. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A): importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun 1980;96:271-7.
45. Hay DW, Muccitelli RM, Tucker SS, et al. Pharmacologic profile of SK&F 104353: a novel, potent and selective peptidoleukotriene receptor antagonist in guinea pig and human airways. J Pharmacol Exp Ther 1987; 243:474-81.
46. Buckner CK, Krell RD, Laravuso RB, Coursin DB, Bernstein PR, Will JA. Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4. J Pharmacol Exp Ther 1986;237:558-62.
47. Jones TR, Davis C, Daniel EE. Pharmacological study of the contractile activity of leukotriene C4 and D4 on isolated human airway smooth muscle. Can J Physiol Pharmacol 1982;60:638-43.
48. Davis C, Kannan MS, Jones TR, Daniel EE. Control of human airway smooth muscle: in vitro studies. J Appl Physiol 1982;53:1080-7.
49. Augstein J, Farmer JB, Lee TB, Sheard P, Tattersall ML. Selective inhibitor of slow-reacting substance of anaphylaxis. Nat New Biol 1973;245: 215-7.
50. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323:1745-8.
51. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-rcceptor antagonist, ICI 204.219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151:1734-9.
52. Spencer DA, Evans JM, Green SE, Piper PJ, Costello JF. Participation of the cysteinyl leukotrienes in the acute bronchoconstrictor response to inhaled platelet activating factor in man. Thorax 1991;46:441-5.
53. Lazarus SC, Wong HH, Watts MJ, Boushey HA, Lavins BJ, Minkwitz MC. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1997;156:1725-30.
54. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337:690-4.
55. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997;52:348-54.
56. Finnerty JP, Wood-Baker R, Thomson H, Holgate ST Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis 1992;145:746-9.
57. 4-receptor antagonist cinalukast. J Allergy Clin Immunol 1997;99:210-5.
58. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise induced bronchospasm by zilcuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931-5.
59. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990;323:1740-4.
60. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopep tide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
61. Dahlen B, Kumlin M, Margolskee DJ, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin sensitive asthmatics. Eur Respir J 1993;6:1018-26.
62. Nassar SM, Bell GS, Foster S, et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax 1994;49:749-56.
63. Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
64. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987;136:740-51.
65. Gauvreau GM, Doctor J, Watson RM, Jordana M, O'Byrne PM. Effects of inhaled budesonide on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1996;154:1267-71.
66. Cartier A, Thomson NC, Frith PA, Roberts R, Hargreave FE. Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. J Allergy Clin Immunol 1982;70:170-7
67. Rasmussen JB, Eriksson LO, Margolskec DJ, Tagari P, Williams VC, Andersson KE. Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90:193-201.
68. Friedman BS, Bel EH, Buntinx A, et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147:839-44.
69. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
70. Roquet A, Dahlen B, Kumlin M, et al. Combined antagonism of leukotricnes and histamine produces predominant inhibition of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir Crit Care Med 1997;155:1856-63.
71. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996;51:1178-84.
72. Diamant Z, Hiltermann JT, van Rensen EL, et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am J Respir Crit Care Med 1997;155:1247-53.
73. Kane GC, Pollice M, Kim CJ, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol 1996;97:646-54.
74. Calhoun WJ, Lavins BJ, Minkwitz MC, Evans R, Gleich GJ, Cohn J. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998;157:1381-9.
75. Anderson SD. Is there a unifying hypothesis for exercise-induced asth-ma? J Allergy Clin Immunol 1984;73:660-5.
76. Rubinstein I, Levison H, Slutsky AS, et al. Immediate and delayed bronchoconstriction after exercise in patients with asthma. N Engl J Med 1987;317:482-5.
77. Kikawa Y, Miyanomae T, Inoue Y, et al. Urinary leukotriene E4 after exercise challenge in children with asthma. J Allergy Clin Immunol 1992; 89:1111-9
78. Reiss TF, Hill JB, Harman E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997;52: 1030-5.
79. Taylor IK, Wellings R, Taylor GW, Fuller RW. Urinary leukotricne E4 excretion in exercise-induced asthma. J Appl Physiol 1992;73:743-8.
80. 4-receptor antagonist. N Engl J Med 1990; 323:1736-9.
81. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984;74:617-22.
82. Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:834-46.
83. 4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
84. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
85. Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
86. Knapp HR, Sladek K, Fitzgerald GA. Increased excretion of leukotriene E4 during aspirin-induced asthma. J Lab Clin Med 1992;119:48-51.
87. Dahlen B, Margolskee DJ, Zetterstrom O, Dahlen SE. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993;48:1205-10.
88. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997;52:523-7
89. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994;150:618-23.
90. Reiss TF, Altman LC, Chervinsky P, et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996;98:528-34.
91. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119:1059-66.
92. Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA 1996;275:931-6.
93. Liu MC, Dube LM, Lancaster J. Acute and chronic effects of a 5-liopxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996;98:859-71.
94. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double blind trial. Arch Intern Med 1998;158:1213-20.
95. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise induced bronchoconstriction in 6 to 14-year-old children with asthma. J Pediatr 1998;133:424-8.
96. Knorr B, Matz I, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. JAMA 1998;279:1181-6.
97. Noonan MJ, Chervinsky P, Brandon M. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11:1232-9.
98. Global initiative for asthma: global strategy for asthma management and prevention: NHLBI/WHO Workshop report. Bethesda, Md.: National Heart, Lung, and Blood Institute, January 1995. (NIH publication no. 95-3659.)
99. Guidelines for the diagnosis and treatment of asthma. Expert panel report 2. Clinical practice guidelines. Bethesda, Md.: National Asthma Education Program, April 1997. (NIH publication no. 97-4051.)
100. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
101. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med 1997;155:1235-40.
102. Singulair (montelukast sodium). West Point, Pa.: Merck, 1998 (package insert).
103. Fischer AR, McFadden CA, Frantz R, et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152:1203-7.
104. Schwartz HJ, Petty T, Dube LM, Swanson LJ, Lancaster JF. A randomized controlled trial comparing zileuton with theophylline in moderate asthma. Arch Intern Med 1998;158:141-8
105. Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
106. ZYFLO filmtab. In: Physicians' desk reference. 52nd ed. Montvale, N.J.: Medical Economics, 1998:474-6.
107. Guidelines for management of asthma in adults. 1. Chronic persistent asthma: statement by the British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma Campaign. BMJ 1990;301:651-3. [Erratum, BMJ 1990;301: 924.]
108. Executive summary: guidelines for the diagnosis and management of asthma. Expert Panel report. Bethesda, Md.: National Asthma Education Program, June 1991. (NIH publication no. 91-3042A.)
109. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
110. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994;154:1349-52.